Development Pipeline

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; BRAF, v-raf murine sarcoma viral oncogene homolog B; CCR8, CC chemokine receptor 8; CD3, cluster of differentiation 3; CDAC, chimeric degradation activating compound; CDK4, cyclin-dependent kinase 4; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; CRC, colorectal cancer; CSF-1R, colony-stimulating factor-1 receptor; DGKζ, diacylglycerol kinase ζ; DLL3, delta-like ligand 3; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; FL, follicular lymphoma; gBRCAm, germline BRCA mutation; GC, gastric cancer; GC-GEJC, gastric cancer-gastroesophageal junction carcinoma; GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HPK1, hematopoietic progenitor kinase 1; 1L, first line; 2L, second line; LA, locally advanced; LAG-3, lymphocyte activation gene 3 protein; mBC, metastatic breast cancer; MCL, mantle cell lymphoma; mCRPC, metastatic castration-resistant prostate cancer; MSI-H, microsatellite instability-high; MTx, maintenance treatment; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PARP, poly(ADP-ribose) polymerase; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3Kδ, phosphoinositide 3-kinase delta; PSOC, platinum-sensitive ovarian cancer; RAF, rapidly accelerated fibrosarcoma; RCC, renal cell carcinoma; R/R, recurrent/refractory; SCLC, small cell lung cancer; SMAC, second mitochondria-derived activator of caspase; STEAP1, Six-Transmembrane Epithelial Antigen of the Prostate 1; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer; UC, urothelial carcinoma.

* in combination with Zanubrutinib.
** +Dexamethasone +/– Carfilzomib.
*** +Azacitidine +/– Posaconazole.
^Primary endpoint met.
^†Leads Biolabs collaboration, BeiGene has ex-China commercial rights.
^‡Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights.
^§Amgen collaboration, BeiGene has China commercial rights.
^¶In collaboration with SpringWorks Therapeutics, Inc.
^^Clinical collaboration with Hutchison Medipharma International.
^††In collaboration with Leap Therapeutics, Inc.
^‡‡Partnership with Mirati Therapeutics, Inc.